BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

BioNTech (NasdaqGS:BNTX) and Gilead Sciences agreed to a clinical trial collaboration to study pumitamig with sacituzumab govitecan in first-line metastatic triple-negative breast cancer. The partners plan to adapt an existing global Phase 3 trial of pumitamig so that it reflects current clinical standards for treating metastatic triple-negative breast cancer. This will be the first worldwide Phase 3 study to test pumitamig in combination with an antibody-drug conjugate, marking a new step...